Generic placeholder image

Current Vascular Pharmacology

Editor-in-Chief

ISSN (Print): 1570-1611
ISSN (Online): 1875-6212

Letter to the Editor

Compelling Indications Should be Listed for Individual Beta-Blockers (Due to Diversity), Not for the Whole Class

Author(s): Goran Koracevic , Sladjana Micic, Milovan Stojanovic *, Dragan Lovic, Dragan Simic , Mirko Colic , Maja Koracevic , Aleksandar Stojkovic and Milenko Paunovic

Volume 19, Issue 4, 2021

Published on: 18 May, 2020

Page: [343 - 346] Pages: 4

DOI: 10.2174/1570161118666200518113833

Next »
[1]
Mukherjee D, Eagle KA. Pharmacotherapy: Current role of β-blockers after MI in patients without HF. Nat Rev Cardiol 2016; 13(12): 699-700.
[http://dx.doi.org/10.1038/nrcardio.2016.176] [PMID: 27786237]
[2]
Hjalmarson A. Cardioprotection with beta-adrenoceptor blockers. Does lipophilicity matter? Basic Res Cardiol 2000; 95(1): 141-5.
[http://dx.doi.org/10.1007/s003950070008] [PMID: 11192352]
[3]
Behera SK, Pradhan A, Sethi R, et al. Invasive assessment of central aortic blood pressure, differential impact of beta blocker vs. non-beta blockers and their correlation with severity of coronary artery disease in hypertensive patients undergoing coronary angiography. J Cardiovasc Dis Res 2019; 10(1): 20-6.
[http://dx.doi.org/10.5530/jcdr.2019.1.4]
[4]
Martínez-Milla J, Raposeiras-Roubín S, Pascual-Figal DA, Ibáñez B. Focus on: Beta-blockers and cardiovascular disease (I) Role of beta-blockers in cardiovascular disease in 2019. Rev Esp Cardiol (Engl Ed) 2019; 72(10): 844-52.
[http://dx.doi.org/10.1016/j.rec.2019.04.014] [PMID: 31402328]
[5]
Ågesen FN, Weeke PE, Tfelt-Hansen P, Tfelt-Hansen J. Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology. Pharmacol Res Perspect 2019; 7(4)e00496
[http://dx.doi.org/10.1002/prp2.496] [PMID: 31338197]
[6]
do Vale GT, Ceron CS, Gonzaga NA, Simplicio JA, Padovan JC. Three generations of β-blockers: history, class differences and clinical applicability. Curr Hypertens Rev 2019; 15(1): 22-31.
[http://dx.doi.org/10.2174/1573402114666180918102735] [PMID: 30227820]
[7]
Cižmáriková R, Habala L, Valentová J, Markuliak M. Survey of pharmacological activity and pharmacokinetics of selected β-adrenergic blockers in regard to their stereochemistry. Appl Sci (Basel) 2019; 9(4): 625.
[http://dx.doi.org/10.3390/app9040625]
[8]
Bennett JM, Siegrist K. evidence-based perioperative management of cardiac medications in patients presenting for noncardiac surgery. Adv Anesth 2016; 34(1): 161-80.
[http://dx.doi.org/10.1016/j.aan.2016.07.010]
[9]
Tatu AL, Elisei AM, Chioncel V, Miulescu M, Nwabudike LC. Immunologic adverse reactions of β-blockers and the skin. Exp Ther Med 2019; 18(2): 955-9.
[http://dx.doi.org/10.3892/etm.2019.7504] [PMID: 31384329]
[10]
Velmurugan BK, Baskaran R, Huang CY. Detailed insight on β-adrenoceptors as therapeutic targets. Biomed Pharmacother 2019; 117109039
[http://dx.doi.org/10.1016/j.biopha.2019.109039] [PMID: 31176173]
[11]
Go JG, Santiago LD, Miranda AC, Jara JD. Effect of beta-blockers on hypertension and heart failure with reduced ejection fraction: A systematic review of randomized controlled trials. Hypertens J 2019; 5(2): 71-6.
[http://dx.doi.org/10.15713/ins.johtn.0157]
[12]
Roston TM, Chua D, Lum E, Krahn AD. Switching between β-blockers: an empiric tool for the cardiovascular practitioner. Can J Cardiol 2019; 35(4): 539-43.
[http://dx.doi.org/10.1016/j.cjca.2019.01.013] [PMID: 30935645]
[13]
Koraćević M, Lalić J, Nedeljković S, Koraćević G. Rebound phenomenon - important and ubiquitous in pharmacotherapy. Acta Med Mediter 2018; 57(4): 148-52.
[http://dx.doi.org/10.5633/amm.2018.0420]
[14]
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27(5): 335-71.
[http://dx.doi.org/10.1016/S0033-0620(85)80003-7] [PMID: 2858114]
[15]
Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016. Available at https://www.escardio.org/static_file/Escardio/Guidelines/ehw128_Addenda.pdf [Accessed on March 21st, 2020]
[16]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 2017; 136(6): e137-61.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[17]
Koraćević G, Sakac D, Pavlović M, Ilić D, Tomasević M, Kostić T. Should we prescribe “vasodilating” beta-blockers in Marfan syndrome to prevent aortic aneurysm and dissection? Vojnosanit Pregl 2012; 69(2): 195-200.
[http://dx.doi.org/10.2298/VSP1202195K] [PMID: 22500376]
[18]
Chobanian AV, Bakris GL, Black HR, et al. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National heart, lung, and blood institute; national high blood pressure education program coordinating committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42(6): 1206-52.
[http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]
[19]
Nerenberg KA, Zarnke KB, Leung AA, et al. Hypertension Canada’s 2018 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults and children. Can J Cardiol 2018; 34(5): 506-25.
[http://dx.doi.org/10.1016/j.cjca.2018.02.022] [PMID: 29731013]
[20]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the european society of cardiology (ESC) and the European Society of Hypertension (ESH). G Ital Cardiol (Rome) 2018; 19(11)(Suppl. 1): 3S-73S.
[PMID: 30520455]
[21]
Umemura S, Arima H, Arima S, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res 2019; 42(9): 1235-481.
[http://dx.doi.org/10.1038/s41440-019-0284-9] [PMID: 31375757]
[22]
Grandi E, Ripplinger CM. Antiarrhythmic mechanisms of beta blocker therapy. Pharmacol Res 2019; 146104274
[http://dx.doi.org/10.1016/j.phrs.2019.104274] [PMID: 31100336]
[23]
Gupta S, Wright HM. Nebivolol: a highly selective beta1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26(3): 189-202.
[http://dx.doi.org/10.1111/j.1755-5922.2008.00054.x] [PMID: 18786089]
[24]
Saad A, Goldstein J, Margalit O, et al. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Pharmacoepidemiol Drug Saf 2020. Epub ahead of print
[http://dx.doi.org/10.1002/pds.4993] [PMID: 32196836]
[25]
Shin J, Choi YJ, Hong GR, et al. Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study. J Hypertens 2020; 38(3): 527-35.
[http://dx.doi.org/10.1097/HJH.0000000000002296] [PMID: 31693535]
[26]
Dézsi CA, Szentes V. The real role of β-blockers in daily cardiovascular therapy. Am J Cardiovasc Drugs 2017; 17(5): 361-73.
[http://dx.doi.org/10.1007/s40256-017-0221-8] [PMID: 28357786]
[27]
Fumagalli C, Maurizi N, Marchionni N, Fornasari D. β-blockers: Their new life from hypertension to cancer and migraine. Pharmacol Res 2020; 151104587
[http://dx.doi.org/10.1016/j.phrs.2019.104587] [PMID: 31809852]
[28]
Poirier L, Tobe SW. Contemporary use of β-blockers: clinical relevance of subclassification. Can J Cardiol 2014; 30(5)(Suppl.): S9-S15.
[http://dx.doi.org/10.1016/j.cjca.2013.12.001] [PMID: 24684855]
[29]
Sharma M, Sharma R, Jain DK, Saraf A. Enhancement of oral bioavailability of poorly water soluble carvedilol by chitosan nanoparticles: Optimization and pharmacokinetic study. Int J Biol Macromol 2019; 135: 246-60.
[http://dx.doi.org/10.1016/j.ijbiomac.2019.05.162] [PMID: 31128197]
[30]
Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-104.
[http://dx.doi.org/10.1093/eurheartj/ehy339] [PMID: 30165516]
[31]
Malachias MVB, Barbosa ECD, Martim JF, Rosito GBA, Toledo JY, Passarelli O. 7th Brazilian Guideline of Arterial Hypertension: Chapter 14 - Hypertensive Crisis. Arq Bras Cardiol 2016; 107(3)(Suppl. 3): 79-83.
[PMID: 27819393]
[32]
Toyoda S, Haruyama A, Inami S, et al. Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure. J Cardiol 2020; 75(2): 140-7.
[http://dx.doi.org/10.1016/j.jjcc.2019.07.011] [PMID: 31444140]
[33]
Oliver E, Mayor F Jr, D’Ocon P. Beta-blockers: historical perspective and mechanisms of action. Rev Esp Cardiol (Engl Ed) 2019; 72(10): 853-62.
[http://dx.doi.org/10.1016/j.rec.2019.04.006] [PMID: 31178382]
[34]
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 2018; 138(13): e210-71.
[http://dx.doi.org/10.1161/CIR.0000000000000548] [PMID: 29084733 ]

© 2022 Bentham Science Publishers | Privacy Policy